ZFIN ID: ZDB-FIG-150506-36
Yao et al., 2014 - Dissecting the differentiation process of the pre-placodal ectoderm in zebrafish. Developmental dynamics : an official publication of the American Association of Anatomists   243(10):1338-51 Full text @ Dev. Dyn.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Anatomical Terms:
Stage Range: 75%-epiboly to 5-9 somites
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage Range: 75%-epiboly to 5-9 somites

Fig. 3

Modulation of Wnt signaling affects the PPR polarity and OEPD development also regulates gata3 and foxi1 expression. A–C: XAV939 treated (5–7 hpf) embryos show enhanced yet loosely packed PPR six4.1 expression (B), compared with the control (A). 3F8 (5–7 hpf) treatment enhances six4.1 expression in caudal PPR and a reduction at the anterior most region (C). D–F: foxi1 expression domains are reduced after XAV939 treatment (E), compared with the control (D). 3F8 (5–7 hpf) treatment anteriorly expands foxi1 expression and the bilateral expression domains are fused rostrally (F). G–I: gata3 expressions are enhanced by XAV939 treatment (H) and reduced after 3F8 treatment (I), compared with control (G). J–L: The OEPD but mid-hindbrain boundary (MHB) expression of pax2a is reduced in embryos treated by XAV939 (K), compared with the control (J). 3F8 (5–7 hpf) treatment expands both MHB and OEPD pax2a expression rostra-caudally (L). 12 hpf. Black arrows indicate the OEPD while blue triangles point to the MHB pax2a. M: Real-time RT-PCR reveals that modulating Wnt signaling adjusts foxi1 and gata3 expression levels at 10.5 hpf. Treating embryos with 3F8 at 5–7 hpf increases foxi1 but reduces gata3 expression. On the other hand, the XAV939 treatment of 5–7 hpf enhances gata3 but cuts down foxi1 expression. 10.5 hpf. *P < 0.05; **P < 0.01 ***P < 0.001 (ANOVA test). N: Different from 10.5 hpf, real-time RT-PCR reveals that modulating Wnt signaling adjusts only gata3 expression levels at 8 hpf. Treating embryos with 3F8 at 5–7 hpf reduces gata3 expression. On the other hand, the XAV939 treatment during 5–7 hpf enhances gata3 expression. 8 hpf. **P < 0.01; ***P < 0.001 (ANOVA test). A–L: Dorsal views with anterior to the left. A–C: 11 hpf; D–I: 10.5 hpf; J–L: 12 hpf. Scale bar = 200 µm.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
foxi1 TU control 1-4 somites neurogenic field ISH
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field ISH
1-4 somites whole organism RTPCR
TU chemical treatment: XAV939 1-4 somites neurogenic field ISH
1-4 somites whole organism RTPCR
gata3 TU control 1-4 somites neurogenic field ISH
TU chemical treatment: Wnt signalling activator 75%-epiboly whole organism RTPCR
1-4 somites neurogenic field ISH
1-4 somites whole organism RTPCR
TU chemical treatment: XAV939 75%-epiboly whole organism RTPCR
1-4 somites neurogenic field ISH
1-4 somites whole organism RTPCR
pax2a TU control 5-9 somites dorsolateral placode ISH
5-9 somites epibranchial field ISH
5-9 somites midbrain hindbrain boundary neural keel ISH
TU chemical treatment: Wnt signalling activator 5-9 somites dorsolateral placode ISH
5-9 somites epibranchial field ISH
5-9 somites midbrain hindbrain boundary neural keel ISH
TU chemical treatment: XAV939 5-9 somites dorsolateral placode ISH
5-9 somites epibranchial field ISH
5-9 somites midbrain hindbrain boundary neural keel ISH
six4b TU control 1-4 somites neurogenic field ISH
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field anterior region ISH
1-4 somites neurogenic field posterior region ISH
TU chemical treatment: XAV939 1-4 somites neurogenic field ISH
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
TU chemical treatment: Wnt signalling activator 75%-epiboly whole organism gata3 expression decreased amount, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field gata3 expression decreased amount, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field foxi1 expression increased distribution, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field foxi1 expression spatial pattern, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field anterior region six4b expression decreased amount, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites neurogenic field posterior region six4b expression increased amount, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites whole organism gata3 expression decreased amount, abnormal
TU chemical treatment: Wnt signalling activator 1-4 somites whole organism foxi1 expression increased amount, abnormal
TU chemical treatment: Wnt signalling activator 5-9 somites dorsolateral placode pax2a expression increased distribution, abnormal
TU chemical treatment: Wnt signalling activator 5-9 somites epibranchial field pax2a expression increased distribution, abnormal
TU chemical treatment: Wnt signalling activator 5-9 somites midbrain hindbrain boundary neural keel pax2a expression increased distribution, abnormal
TU chemical treatment: XAV939 75%-epiboly whole organism gata3 expression increased amount, abnormal
1-4 somites neurogenic field foxi1 expression decreased amount, abnormal
1-4 somites neurogenic field gata3 expression increased amount, abnormal
1-4 somites neurogenic field six4b expression spatial pattern, abnormal
1-4 somites whole organism foxi1 expression decreased amount, abnormal
1-4 somites whole organism gata3 expression increased amount, abnormal
5-9 somites dorsolateral placode pax2a expression decreased distribution, abnormal
5-9 somites epibranchial field pax2a expression decreased distribution, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Developmental dynamics : an official publication of the American Association of Anatomists for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Dev. Dyn.